ARVN News and Press, Arvinas Inc. From 01/23/23

Summary Kymera Therapeutics, Inc.'s KT-474 HS/AD data de-risked the IRAK4 protein degradation platform, as did Sanofi's partnering. However, more differentiating data seems to be needed in these indications and with IRAK4 inhibitors. I also wish to see more data from self-owned prod...

Bayer ( OTCPK:BAYZF ) ( OTCPK:BAYRY ) said on Thursday that it is collaborating with Oerth Bio to develop the next generation of sustainable crop protection products. The German conglomerate added that Oerth's protein degradation technology PROTAC provides an innova...

Summary Verona Pharma is a biopharmaceutical company involved in studies and product development related to respiratory diseases. Ensifentrine is the main company product and is based on the analysis of great unmet medical demand in COPD. The latest clinical trials on Ensifentrine u...

Arvinas ( NASDAQ: ARVN ) shares reached the lowest level in more than two years on Monday after the company and its partner Pfizer ( NYSE: PFE ) announced data from the ongoing Phase 1/2 study for the protein degrader ARV-471 in combination with CDK4/6 inhibitor Ibrance (palbocicl...

NEW HAVEN, Conn., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., President and Chief Executive Officer of Arvinas, will present a ...

NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Brad Margus, M.B.A., has stepped down from the company’s Board and Everett Cunn...

NEW HAVEN, Conn., June 02, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual ...

-- In honor of 20 years of targeted protein degradation, Arvinas announces $25,000 prize to recognize the efforts of an up-and-coming researcher in the field of targeted protein degradation – -- Global nomination deadline of August 1, 2022 -- NEW HAVEN, Conn., Jun...

Piper Sandler cut its price target (PT) on 17 companies in the biotech space reflecting the recent pullback in the stock and prevailing market conditions. Piper Sandler also noted that biotech valuations have re-rated. Following are the stocks which saw their PT lowered: Gene editing com...

Arvinas announced decent data from ARV-110 in February. The market may have expected more. I will continue to hold. For further details see: Arvinas: Still Holding, Just Not Buying More